Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Myriad Genetics Q3 Sales $205.700M Beat $204.897M Estimate

Author: Benzinga Newsdesk | November 03, 2025 04:08pm
Myriad Genetics (NASDAQ:MYGN) reported quarterly sales of $205.700 million which beat the analyst consensus estimate of $204.897 million by 0.39 percent. This is a 3.56 percent decrease over sales of $213.300 million the same period last year.

Posted In: MYGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist